SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia

Published:2020-12 Issue:12 Volume:22 Page:714-724
ISSN:1476-5586
Container-title:Neoplasia
language:en
Short-container-title:Neoplasia

Author:

Fan Lei,Wang Chao,Zhao Liwen,Wang Zhiqiang,Zhang Xian,Liu Xiaorong,Cao Lei,Xu Wei,Li Jianyong

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research

Reference55 articles.

1. Non-Hodgkin lymphoma;Shankland;Lancet,2012

2. Epidemiology and etiology of non-Hodgkin lymphoma;Chiu;Cancer Treat Res,2015

3. SEER Stat Fact Sheets: Non-Hodgkin lymphoma,2012

4. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016

5. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CCL17, CCL22 and their receptor CCR4 in hematologic malignancies;Discover Oncology;2024-09-06

2. Aflatoxin B1 and Epstein–Barr virus-induced CCL22 expression stimulates B cell infection;Proceedings of the National Academy of Sciences;2024-04-04

3. Targeting MYC-driven lymphoma: lessons learned and future directions;Cancer Drug Resistance;2023

4. Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration;Cancer Chemotherapy and Pharmacology;2022-12-27

5. Small molecule-based immunomodulators for cancer therapy;Acta Pharmaceutica Sinica B;2022-12